ACIFORMULA share price
ACI Formulations PLC · Pharmaceuticals & Chemicals · Category A
Price
Closing prices, 19 Nov 2026 Live prices free with an account
- Previous close
- ৳126.80
- Day range
- No trade
- Volume
- 0
- Turnover
- —
ACIFORMULA price over the last year
Daily closing prices from DSE, not adjusted for bonus or rights issues.
Reported earnings and NAV
| Period | EPS | NAV / share | NOCFPS |
|---|---|---|---|
| FY27 Q1 | 0.22 | 81.25 | -7.00 |
| FY26 Annual | 7.96 | 81.02 | -4.11 |
| FY26 Q3 | 1.76 | 81.27 | -6.79 |
| FY26 Q2 | 4.64 | 79.50 | -4.01 |
| FY26 Q1 | 1.85 | 77.36 | -6.48 |
| FY25 Annual | 7.85 | 75.51 | 0.66 |
| FY25 Q3 | 1.89 | 75.59 | 3.53 |
| FY25 Q2 | 4.40 | 73.70 | 2.95 |
Per-share figures in taka, as published on DSE. Interim EPS is for the period, not annualised.
Latest DSE announcements
-
Trading of the shares of the company will resume on 22-Nov-2026.
-
Trading of the shares of the company will remain suspended on record date i.e., 19-Nov-2026.
-
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 17.11.2026 to 18.11.2026 and trading of the shares will remain suspended on record date i.e., 19.11.2026.
-
(Q1 Un-audited): Consolidated EPS was Tk. 0.22 for July-September 2026 as against Tk. 1.85 for July-September 2025; Consolidated NOCFPS was Tk. (7.00) for July-September 2026 as against Tk. (6.48) for July-September 2025. Consolidated NAV per share was Tk. 81.25 as on September 30, 2026 and Tk. 81.02 as on June 30, 2026. Reasons for deviation: Consolidated revenue increased by 3.29% over SPLY GP decreased by 11.87% due to increase of raw material and packing material price (cont.)
-
(Cont. News of ACIFORMULA): in the international market. On other hand, overall operating expenses increased by 22% due to inflationary effects and higher cost of exports. Additionally, financing cost increased by 22% due to higher working capital utilization. Overall effect resulted consolidated profit after tax of Tk. 10.63 Mn against Tk 87.70 Mn of SPLY resulting in lower consolidated EPS. Consolidated NOCFPS decreased due to ensure adequate inventory in the upcoming season over SPLY. (end)
-
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2026 at 2:45 PM to consider, among others, Un-Audited Financial Statements for the First Quarter (Q1) period ended September 30, 2026.
Other Pharmaceuticals & Chemicals shares
| Ticker | Price | % | Turnover |
|---|---|---|---|
| ASIATICLABAsiatic Laboratories Limited | 116.70 | +1.83% | ৳16.3Cr |
| WATACHEMWata Chemicals Limited | 183.10 | +8.22% | ৳11.0Cr |
| SQURPHARMASquare Pharmaceuticals PLC. | 209.70 | -0.29% | ৳8.4Cr |
| ACMELABThe ACME Laboratories Limited | 77.50 | -3.73% | ৳3.2Cr |
| ORIONINFUOrion Infusion Ltd. | 202.80 | -0.44% | ৳2.9Cr |
| ACMEPLACME Pesticides Limited | 24.50 | -0.41% | ৳2.8Cr |
ACIFORMULA: common questions
What is ACIFORMULA's share price?
ACIFORMULA closed at ৳126.80 on the Dhaka Stock Exchange (Closing prices, 19 Nov 2026), 0.00 (0.00%) from the previous close of ৳126.80.
What is ACIFORMULA's 52-week high and low?
Between 23 Nov 2025 and 18 Nov 2026, ACIFORMULA traded as high as ৳189.20 and as low as ৳120.30 on DSE.
What is ACIFORMULA's P/E ratio?
At ৳126.80, ACIFORMULA's P/E ratio is 15.93, on its FY26 earnings per share of ৳7.96.
What dividend did ACIFORMULA declare?
For 2026, ACI Formulations PLC declared a 20% cash dividend. Percentages are of the ৳10 face value.
Which sector is ACIFORMULA in?
ACI Formulations PLC is listed in the Pharmaceuticals & Chemicals sector of the Dhaka Stock Exchange, in category A.
Prices, trades and company figures are from the Dhaka Stock Exchange; prices are at least 15 minutes old. Trakkr is not affiliated with DSE, and nothing here is investment advice.